BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
01 août 2022 07h00 HE
|
BioXcel Therapeutics
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatmentOver 142 million opioid prescriptions dispensed in the U.S. in 20201More...
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
26 juil. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors
05 juil. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
07 juin 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
20 mai 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
09 mai 2022 07h00 HE
|
BioXcel Therapeutics
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4...
BioXcel Therapeutics to Present at Three Upcoming Investor Conferences
05 mai 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
03 mai 2022 07h00 HE
|
BioXcel Therapeutics
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023 Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022 NEW HAVEN, Conn., May 03, 2022 (GLOBE...
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
26 avr. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to...
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
19 avr. 2022 07h05 HE
|
BioXcel Therapeutics
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth...